iOmx Therapeutics
Germany - MartinsriedBiotechnology
Focus: iOmx Therapeutics is a cancer immunotherapy-focused biotech company headquartered in Germany specializing in oncology treatments. The company is in early-stage development with a single Phase 1/2 program and minimal public visibility.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
1
Should You Work at iOmx Therapeutics?
AI assessmentEarly-stage, high-risk immunotherapy biotech suitable only for scientists seeking equity upside and hands-on roles; limited career stability and advancement paths.
Why Work Here
- Ground-floor opportunity in cancer immunotherapy, a high-growth therapeutic area with significant unmet need and industry investment
- Early-stage company structure allows direct impact on drug development and potential equity upside if program succeeds
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OMX-0407
Solid TumorClinical Trials (1)
NCT05826600A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
Phase 1/2Help build intelligence for iOmx Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.